BioInvent and Servier enter cancer collaboration
BioInvent to provide antibody discovery and in-house research
BioInvent International of Sweden and French pharmaceutical company Les Laboratoires Servier have agreed an antibody collaboration on an oncology target involved in tumour cell metabolism.
BioInvent will receive payments of more than €11m, as well as royalty on future sales of the product.
Under the terms of the agreement, BioInvent will screen Servier’s n-CoDeR library for antibodies that are specific to the undisclosed target. Servier will also have access to BioInvent's pre-clinical capacities in selecting an antibody candidate for development.
Svein Mathisen, president and ceo of BioInvent, said: ‘Oncology is a prioritised area for BioInvent as for Servier and we look forward to joining our knowledge to theirs in this area.’
The Bioinvent n-CoDeR library will be used in combination with a functional assay set up at Servier to select antibody candidates.
‘This is expected to enable us to develop one of the first monoclonal antibodies targeting tumour cell metabolism, an approach anticipated to have major therapeutic potential,’ said Stéphane Depil, who heads oncology R&D at Servier.
